Managing incontinence due to detrusor instability

Drug and Therapeutics Bulletin

Volumn 39, Issue 8, 2001, Pages 59-64

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; ESTROGEN; FLAVOXATE; IMIPRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPANTHELINE BROMIDE; PROPIVERINE; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG; URISPAS 200;

ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETRUSOR DYSSYNERGIA; FEMALE; FLUID INTAKE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; MEDICAL SPECIALIST; MICTURITION DISORDER; PATIENT REFERRAL; PHYSIOTHERAPY; PRIMARY MEDICAL CARE; STRESS INCONTINENCE; TRAINING; ULTRASOUND; URINALYSIS; URINE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0034882946     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2001.39859     Document Type: Article

References (41)

1. Management of urinary incontinence in women
2. The standardization and terminology of lower urinary tract function
3. Urinary Incontinence: Does it increase risk for falls and fractures?
4. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality
5. Assessment and treatment of urinary incontinence
6. Validity study of the severity index, a simple measure of urinary incontinence in women
7. Caffeine: Does it affect your bladder?
8. A prospective trial of bladder training as treatment for detrusor instability
9. Controlled trial of bladder drill for detrusor instability
10. Bladder training for urinary incontinence in adults (Cochrane Review)
11. Conservative management of incontinence
12. Pelvic floor muscle training for urinary incontinence in women (Cochrane Review)
13. A randomised controlled trial of urodynamic investigations prior to conservative treatment of urinary incontinence in the female
14. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
15. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers
16. Oxybutynin chloride in the management of idiopathic detrusor instability
17. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride
18. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability
19. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
20. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
21. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo
22. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence
23. Double-blind crossover comparison of flavoxate and oxybutynin in women affected by urinary urge syndrome
24. Oxybutynin: Is it safe?
25. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose of oxybutynin
26. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
27. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: Urodynamic evaluation
28. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity
29. Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial
30. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study
31. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder
32. Efficacy of trospium chloride in patients with detrusor instability: A placebo-controlled, randomized, double-blind, multicentre clinical trial
33. Trospium chloride (Spasmo-lytR) in patients with motor urge syndrome (detrusor instability): A double-blind, randomised, multicentre, placebo-controlled study
34. Trospium chloride versus oxybutynin: A randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia
35. Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge-syndrome: A double-blind, controlled, multicentre clinical trial
36. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: A double-blind, placebo-controlled, multicentre clinical trial
37. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia - A double-blind, placebo-controlled clinical trial
38. Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability
39. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female